🔎 Trials Near Me

Home › Bile Duct Cancer (Cholangiocarcinoma) › Illinois

Bile Duct Cancer (Cholangiocarcinoma) clinical trials in Illinois

8 studies for Bile Duct Cancer (Cholangiocarcinoma) are looking for participants at sites in Illinois.

Cities in Illinois

A Study of PHST001 in Advanced Solid Tumors

  • University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

  • City of Hope - Chicago Cancer Center (Site 128), Zion
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07265674

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

  • University Chicago Medicine, Chicago
  • Carle Cancer Center, Urbana
  • Midwestern Regional Medical Center, City of Hope Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05732831

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

  • University Of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05874414

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  • The University of Chicago Medical Center - Oncology, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07169734

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chicago
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

The Dragon PLC Trial (DRAGON-PLC)

  • Rush University Medical Center, Chicago
Recruiting
Ages 18 and older · All sexes · Updated May 15, 2025 · NCT06914648

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.